AJG series: Molecular biology for clinicians

American Journal of Gastroenterology

Volumn 104, Issue 10, 2009, Pages 2583-2587

  Saito, Yuri A ^a   Talley, Nicholas J ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ANTIBIOTIC AGENT; AZATHIOPRINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; FLUOROURACIL; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; OXALIPLATIN; PROKINETIC AGENT; PROTON PUMP INHIBITOR; SPASMOLYTIC AGENT; TACROLIMUS; THIOPURINE METHYLTRANSFERASE; TRICYCLIC ANTIDEPRESSANT AGENT;

CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; DRUG ABSORPTION; DRUG METABOLISM; DRUG RESPONSE; DYSPEPSIA; ENTERITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GENETIC ANALYSIS; GENETIC VARIABILITY; HELICOBACTER INFECTION; HUMAN; IRRITABLE COLON; LIVER TRANSPLANTATION; MEDICAL INFORMATION; MOLECULAR BIOLOGY; PATIENT EDUCATION; PEPTIC ULCER; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; GENETIC SCREENING; GENETICS; GENOMICS;

GASTROINTESTINAL DISEASES; GENETIC SCREENING; GENOMICS; HUMANS; PHARMACOGENETICS;

EID: 70350501309     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.319     Document Type: Review

References (22)

1. den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet 2001; 109:121-124
2. Egan LJ, Derijks LJ, Hommes DW. Pharmacogenomics in inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4:21-28
3. Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut 2001; 48:591-592
4. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004; 95:2-8
5. Kawamura M, Ohara S, Koike T et al. The Effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacolther 2003; 17:965-973
6. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23:460-471
7. Salonga D, Danenberg KD, Johnson M et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6:1322-1327
8. Milano G, Etienne MC, Pierrefite V et al. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999; 79:627-630
9. Wei X, McLeod HL, McMurrough J et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996; 98:610-615
10. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22:529-536
11. Ando Y, Saka H, Ando M et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60:6921-6926
12. Iyer L, Das S, Janisch L et al. UGT1A1* 28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2:43-47
13. Stoehlmacher J, Ghaderi V, Iobal S et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001; 21 (4B):3075-3079
14. Holtmann G, Siffert W, Grote E et al. G-protein mediated receptor-cell-coupling as a predictor for the long term response to treatment in patients with functional dyspepsia. Gastroenterology 2003; 124:A80
15. Furuta T, Shirai N, Watanabe F et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacolther 2002; 72:453-460
16. Schwab M, Schaeffeler E, Klotz U et al. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacolther 2004; 76:201-209
17. Colombel JF, Ferrari N, Debuysere H et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118:1025-1030
18. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006; 25:1629-1638
19. Urano W, Taniguchi A, Yamanaka H et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002; 12:183-190
20. Camilleri M, Atanasova E, Carlson PJ et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123:425-432
21. Amirimani B, Ning B, Deitz AC et al. Increased transcriptional activity of the CYP3A4* 1B promoter variant. Environ Mol Mutagen 2003; 42:299-305
22. Zhao Y, Song M, Guan D et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc 2005; 37:178-81.